What Is 5-MeO-DMT (Bufo)

5-MeO-DMT is a tryptamine psychedelic that acts on the brain’s serotonin system. Its full chemical name is 5-methoxy-N,N-dimethyltryptamine. Mebufotenin is another name used in scientific and pharmaceutical contexts.

The molecule occurs naturally in some plants and in the defensive secretion of the Sonoran Desert toad, scientifically named Incilius alvarius. It can also be produced synthetically. Toad secretion is a biologically variable mixture, while a characterized synthetic research product contains a defined molecule and formulation.

People have used 5-MeO-DMT in ceremonial, spiritual and non-clinical settings. Scientists are now studying pharmaceutical formulations in controlled trials. These contexts differ in screening, oversight and available evidence.

Bufo is a common informal name for experiences involving secretion from the Sonoran Desert toad. The term comes from the animal’s former scientific name, Bufo alvarius. Its accepted scientific name is now Incilius alvarius.

Calling all 5-MeO-DMT “Bufo” creates confusion because the molecule can come from sources unrelated to a toad. “Toad venom” is also a popular phrase, although “defensive secretion” or “toad secretion” is more biologically accurate.

There is no scientific evidence that toad-derived 5-MeO-DMT is inherently more healing, powerful or spiritually valid than chemically identical synthetic 5-MeO-DMT. People can hold personal or ceremonial views about the source, while factual claims of superiority require evidence.

5-MeO-DMT interacts with several serotonin receptors, especially 5-HT1A and 5-HT2A receptors. These receptor systems help regulate perception, mood, cognition and conscious experience. Its receptor profile differs from that of many classic psychedelics, which may help explain its distinctive effects.

Human studies show rapid absorption and elimination in the formulations studied, along with marked short-term changes in brain electrical activity. These findings describe biological correlates, but they do not yet establish exactly how an experience may lead to lasting psychological change.

The body primarily breaks down 5-MeO-DMT through monoamine oxidase A, or MAO-A. Combining it with monoamine oxidase inhibitors, or MAOIs, is a major safety concern because the interaction can greatly increase and prolong exposure, with reported cases of serotonin toxicity and death.

No description predicts one person’s experience. Reports range from profound peace and unity to fear, confusion or little memory of the most intense period.

Frequently reported effects include a rapid loss or alteration of ordinary self-awareness; a sense of unity, boundlessness or non-dual awareness; changes in the perception of time, space and the body; intense energy, vibration or release; awe, love, gratitude or sacredness; and, for some people, panic, disorientation, crying, shaking, vocalizing or involuntary movement.

Compared with N,N-DMT, 5-MeO-DMT is often described as less visually elaborate and more immersive or formless, although some people report light, color or imagery. No outcome is guaranteed, and an intense or mystical experience does not by itself establish safety or lasting benefit.

For rapidly absorbed forms described in human research, the central psychedelic experience is commonly reported to last about 15 to 20 minutes, with a broader period of altered effects that can approach 30 to 60 minutes or longer. Onset, peak and resolution vary by formulation, individual metabolism and other factors.

In a controlled Phase 1 study of an intranasal pharmaceutical formulation, peak blood concentration occurred at about 8 to 10 minutes and the mean terminal elimination half-life was under 27 minutes. That time course should not be assumed to match toad secretion or every other formulation.

“Short-acting” does not mean psychologically minor. Emotional sensitivity, fatigue, insight, confusion, sleep changes or reactivation-like experiences may continue after the acute effects end, and integration may take days, weeks or longer.

5-MeO-DMT and N,N-DMT are related tryptamines, but they are different molecules with different receptor profiles and commonly reported experiences. 5-MeO-DMT is often described as rapid, immersive and less visually elaborate, while N,N-DMT more commonly produces vivid imagery and narrative-like experiences.

Ayahuasca is not the same as either molecule used alone. It combines DMT-containing plants with MAO-inhibiting compounds that make oral DMT active and substantially change its duration, pharmacology and interaction risks.

The term “DMT” should not be used as shorthand for 5-MeO-DMT. Safety information for one cannot automatically be transferred to the other, and ayahuasca’s MAOI component creates distinct interaction concerns.

5-MeO-DMT is powerful, and a brief duration does not remove medical, psychological or situational risk. Reported acute effects include nausea, vomiting, headache, anxiety, fear, confusion, changes in heart rate or blood pressure, loss of motor control and overwhelming intensity. A person may temporarily be unable to communicate or protect their body, creating secondary risks such as falls or aspiration.

Other concerns include serotonin toxicity, particularly with MAOIs; reactivations; panic, derealization, depersonalization, insomnia, mania-like symptoms or psychotic symptoms; and rare medical emergencies or deaths in complex cases involving other substances.

Carefully screened clinical trials have generally reported mostly mild or moderate short-term adverse events, but the studies remain small and cannot establish broad safety in community settings. If someone collapses, has a seizure, has trouble breathing, develops severe chest pain, becomes dangerously hot or cannot be awakened, call emergency services immediately.

There is no online checklist that can declare someone safe for 5-MeO-DMT. Responsible screening includes medical and psychiatric history, current symptoms, medications, supplements, recent substance use and personal and family risk factors.

Clinical psychedelic studies commonly exclude or apply special caution to people with personal or close family histories of psychotic disorders or bipolar-spectrum illness, uncontrolled cardiovascular disease, significant neurological conditions, seizure risk, pregnancy or breastfeeding.

MAOIs present a particularly serious and documented interaction risk. Other serotonergic medications, stimulants, cardiovascular drugs, psychiatric medicines, supplements and recreational substances may also change risk. Never abruptly stop an antidepressant or another prescribed medication to qualify for a psychedelic experience. Medication decisions belong with the prescribing clinician.

A trustworthy program should clearly explain its screening, informed consent, qualifications, boundaries, emergency plan, product testing, adverse-event response and follow-up. Guaranteed-healing promises or claims that spiritual protection replaces medical preparation are serious warning signs.

Research on 5-MeO-DMT has advanced from surveys and small safety studies to a randomized Phase 2b depression trial. Potential therapeutic use remains investigational, and no 5-MeO-DMT product is currently FDA-approved.

A 2026 randomized, double-blind trial enrolled 81 adults with treatment-resistant depression. Forty participants received inhaled pharmaceutical mebufotenin, called GH001 in development, and 41 received placebo. At day eight, the adjusted difference on a standard depression-rating scale favored GH001 by 15.5 points. Remission was reported in 23 of 40 GH001 participants and 0 of 41 placebo participants.

This is meaningful controlled evidence for one pharmaceutical formulation in a carefully screened and supported clinical population. It does not establish the same effects for toad secretion, ceremony or retreat settings, or the general population. Larger confirmatory trials, longer follow-up and independent replication are still needed.

Many people describe 5-MeO-DMT experiences with spiritual words such as union with God or Source, remembrance, rebirth, divine love, non-duality, surrender or the dissolution of separation. Those interpretations can be deeply meaningful and deserve respectful listening.

Science uses a different frame. Researchers can measure reports of unity, sacredness, timelessness, ineffability and ego dissolution. A questionnaire score neither verifies nor disproves a metaphysical conclusion. It documents features of a subjective experience.

Both honesty and reverence matter. A person can say, “I experienced this as contact with the divine,” without presenting that interpretation as a fact every participant must accept. Ethical care also leaves room for experiences that are confusing, frightening, emotionally neutral or understood in non-spiritual ways.

An intense experience is an event. Integration is the continuing process of making sense of it and deciding what, if anything, belongs in daily life.

Integration may involve rest, reflection, journaling, grounded conversation, psychotherapy, spiritual counsel or practical changes in relationships and behavior. It should support critical thinking instead of pressuring someone to accept a facilitator’s interpretation. Grand conclusions made immediately after an altered state may feel certain while still requiring time and discernment.

Professional support becomes especially important when someone experiences persistent insomnia, panic, mania-like energy, paranoia, suicidal thoughts, an inability to function, prolonged derealization or distressing reactivations. Integration is not a substitute for emergency, medical or psychiatric care.

In the United States, 5-MeO-DMT and its salts and isomers are federally classified as Schedule I controlled substances. State, local and international laws vary, and decriminalization in one jurisdiction does not automatically make possession, facilitation, sale or commercial activity lawful. Religious-freedom questions are fact-specific and do not create an automatic exemption.

The Sonoran Desert toad faces pressures from habitat loss, collection and growing demand for its secretion. Scientific literature has raised concerns about exploitation and animal welfare. Because 5-MeO-DMT can be produced synthetically, no toad is pharmacologically required to produce the molecule.

Ethical evaluation should include wildlife impact, truthful source disclosure and the avoidance of unsupported claims that animal-derived secretion is spiritually superior. This information is educational and is not legal advice.